ASCO 2016 | Targeting RAS oncogenes in patients with NRAS-mutated melanoma

Grant McArthur

Grant McArthur, MBBS, BMedSci, PhD, FRACP from the Peter MacCallum Cancer Centre, Melbourne, Australia gives an overview of mutations in melanoma and developments in therapies to combat such mutations. 70-80% of melanoma cases have activating mutations in BRAF MEK/ERK pathway. 40-50% have mutations in BRAF and 15-20% have mutations in NRAS. Prof. Grant McArthur explains the first positive Phase III trial called NEMO of binimetinib targeting the RAS oncogene in patients with NRAS-mutated melanoma (NCT01763164). Meaningful improvements in progression-free survival (PFS) have been seen and Prof. McArthur finds this promising for the future. Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter